{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Insulin developer MannKind announces that Sanofi is ending agreement in which it had rights to market inhaled insulin called Afrezza; drug has not met sales expectations since Food and Drug Administration approval.", "type_of_material": "News", "word_count": "914", "lead_paragraph": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "pub_date": "2016-01-06T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Sanofi Ends Marketing Deal With Developer of Inhaled Insulin", "print_headline": "Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out"}, "snippet": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "multimedia": [{"height": 126, "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Sanofi SA", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "MannKind Corporation", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Mann, Alfred E", "name": "persons"}, {"rank": "4", "is_major": "N", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Diabetes", "name": "subject"}], "blog": [], "_id": "568c05fb38f0d803f4a0c464", "source": "The New York Times"}